Compare LI & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LI | WST |
|---|---|---|
| Founded | 2015 | 1923 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 25.6B |
| IPO Year | 2019 | 2004 |
| Metric | LI | WST |
|---|---|---|
| Price | $12.27 | $348.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $19.66 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 3.4M | 642.4K |
| Earning Date | 05-28-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.30% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 4.07 |
| Revenue | N/A | ★ $2,886,900,000.00 |
| Revenue This Year | $18.98 | $6.76 |
| Revenue Next Year | $22.72 | $6.22 |
| P/E Ratio | ★ $29.50 | $85.02 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $11.65 | $223.83 |
| 52 Week High | $26.94 | $386.00 |
| Indicator | LI | WST |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 51.04 |
| Support Level | $12.06 | $323.60 |
| Resistance Level | $12.39 | $367.66 |
| Average True Range (ATR) | 0.29 | 7.06 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 4.85 | 63.76 |
Li Auto is one of China's leading new energy vehicle manufacturers. Founded in 2015, the company designs, develops, manufactures, and sells premium smart NEVs with a particular focus on family size premium SUVs and MPVs. Li Auto started volume production of its first model—the Li One, an SUV that is a premium plug-in electric vehicle- in November 2019. Besides PHEVs, its product portfolio now extends to EVs that are fully battery-powered, reaching a wide audience. It has sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger NEV market.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.